Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EU Commission Misses Chance To Lead On Drug Patent Settlements

Executive Summary

The European Commission has published its annual report on the monitoring of patent settlements in Europe but has again failed to offer pharma firms the guidance and legal certainty they need.

You may also be interested in...

Drug Makers Relieved As Europe's Unitary Patent Gets Predictable Boost

The Advocate General of the Court of Justice of the European Union has dismissed Spain’s second challenge to the unitary patent, offering more legal certainty for drug manufacturers and pointing the way towards reduced litigation costs.

European Commission May Pursue More Antitrust Actions Against Pharma

The EC is scrutinizing pharma practices that may delay generic entry and advocating changes in the patent system.

Quelle Surprise! EU Investigators Raid Pharma Firms

Government officials investigate possible obstacles to competition in the drug industry, expect a preliminary report this fall.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts